| 培美曲塞在非小细胞肺癌治疗中的研究进展 |
| |
| 引用本文： | 陈闪闪,冯奉仪. 培美曲塞在非小细胞肺癌治疗中的研究进展[J]. 肿瘤学杂志, 2007, 13(1): 22-25 |
| |
| 作者姓名： | 陈闪闪 冯奉仪 |
| |
| 作者单位： | 中国医学科学院肿瘤医院,北京,100021 |
| |
| 摘 要： | 培美曲塞（Pemetrexed，Alimta^R）是一种新型的多靶点抗叶酸药物．作为局部晚期或转移性非小细胞肺癌的二线治疗药物，目前已经有多个临床研究表明．培美曲塞单药或与其它药物联合在非小细胞肺癌的治疗中均获得显著疗效。该文对此作一回顾。
|
| 关 键 词： | 培美曲塞 癌,非小细胞肺 |
| 文章编号： | 1671-170X(2007)01-0022-04 |
| 修稿时间： | 2006-09-27 |
Progress of Pemetrexed in the Treatment for Non-small Cell Lung Cancer |
| |
| CHEN Shan-shan,FENG Feng-yi. Progress of Pemetrexed in the Treatment for Non-small Cell Lung Cancer[J]. Journal of Chinese Oncology, 2007, 13(1): 22-25 |
| |
| Authors: | CHEN Shan-shan FENG Feng-yi |
| |
| Abstract: | Pemetrexed(AlimtaR) is a multitargeted antifolate. As a second-line therapeutic agent for local advanced or metastatic non-small cell lung cancer (NSCLC), several clinical studies reveal that pemetrexed has shown significant antitumor activity in the treatment for NSCLC, either as a single agent or in combination with other agents. This paper reviews the progress of pemetrexed in treatment for NSCLC. |
| |
| Keywords: | pemetrexed carcinoma non-small cell lung |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
